For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits ...

Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

A genetic test could guide the use of hormone therapy for men with recurrent prostate cancer after surgery, according to data ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

Despite SBRT (radiation) to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...

The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...

(UroToday.com The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Beth Neilsen ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT) ...